Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 6576 逸達. Please read: https://finlab.finance/en/setup?stock=6576

No install, open FinLab Studio

6576

逸達 Biotech & Healthcare As of 2026-06-17 Updated daily after market close

quality needs a look, fair valuation.

1 active signal
Revenue ≥20%
This page refreshes daily after the close. Add 逸達 to your watchlist to track signal changes on your next visit.
Valuation 9Quality 51Growth 99Momentum 53Chips 30

Is 逸達 a buy? Fundamentals and valuation first

  • Weak profitability.Operating margin is in the 3th market percentile. Latest quarterly ROE ≈ 35.0%.

  • Foreign investors are net selling.Foreign 20-day net flow ≈ -1.2% of volume (net sell).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 749.5%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Bullish +0.96
BearishNeutralBullish

Single-sided accumulation, concentration rising — bullish

  • Single-sided accumulation, concentration rising — bullish
  • 國票-安和 holds 5,170 lots
  • sellers have 54 lots left, ~43 sessions to clear

Window from 2026-01-17 · Price -1% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 國票-安和 has accumulated 5,170 lots since the start (sold 0%), holding.
  • Main distributor 凱基-基隆 peaked at 97 lots, has sold 28%, 70 left, paused recently.
  • TDCC big holders (absolute) >1000-lot holders +3.81pp, mid holders -1, retail -3.44pp — concentration shifting upward.
  • Foreign hedge-desk net short Net short -277 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
國票-安和凱基-台北統一統一-敦南台灣摩根士丹利元大-北府
Distributing
凱基-基隆美商高盛玉山-板橋華南永昌-台中玉山-台中元大-林園
Desks
own scale
元大-仁愛兆豐證券玉山-城中臺銀-金山
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 國票-安和 +5,170
    sold 0%
  • 凱基-台北 +822
    sold 9%
  • 統一 +446
    sold 1%
  • 統一-敦南 +318
    sold 0%· still adding
  • 台灣摩根士丹利 +142
    sold 11%· still adding
  • 元大-北府 +111
    sold 0%

Distributing

  • 凱基-基隆 70 left
    sold 28%· paused recently
  • 美商高盛 16 left
    sold 81%· paused recently
  • 玉山-板橋 26 left
    sold 37%· ~43 sessions to clear
  • 華南永昌-台中 17 left
    sold 26%· paused recently
  • 玉山-台中 8 left
    sold 50%· paused recently
  • 元大-林園 4 left
    sold 73%· paused recently

Desks

  • 元大-仁愛 -495
    unclassified
  • 兆豐證券 -461
    unclassified
  • 玉山-城中 -195
    unclassified
  • 臺銀-金山 -176
    unclassified
Still selling 54 lots ~43 sessions to bottom at most
Recent buy/sell force +480 absorbed / -26 sold buyers slightly ahead
Hedge-desk net short -99 lots potential cover-buying, not selling pressure
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Direction matches: big-holder share rose while retail share fell.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 749.55%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

34 historical occurrences (since 2018-10-11)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 51.5%, Sample 33, Median +0.49%, Excess -2.37%, Beat mkt rate 33.3%；60-day: Win 37.5%, Sample 32, Median -3.07%, Excess -5.57%, Beat mkt rate 31.2%；120-day: Win 46.9%, Sample 32, Median -3.84%, Excess -13.54%, Beat mkt rate 21.9%

120 days after: historical avg -0.53%

20-day -0.15%
60-day 0%
120-day -0.53%
20-day
60-day
120-day
Win
51.5%
37.5%
46.9%
Sample
33
32
32
Median
+0.49%
-3.07%
-3.84%
Excess
-2.37%
-5.57%
-13.54%
Beat mkt rate
33.3%
31.2%
21.9%

Over 32 occurrences, 120-day forward avg declined 0.53%, lagged the market by 13.54 pts; win rate 46.9%.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

23 times historically; 60-day forward avg +6.58%, win rate 34.8%, beating the market by +1.87 pts on average.

What does 逸達 do? Company profile

生技醫療業；新藥研發、長效注射劑型與創新小分子藥物 上櫃（櫃買中心，TPEx）

Overview

逸達生物科技股份有限公司成立於2013年2月8日，股票於2018年6月29日在櫃買中心上櫃，總部位於台北市南港區三重路19-3號9樓之2，營運跨台灣與美國。董事長兼總經理為創辦人簡銘達博士，財務長及發言人為詹孟恭。Yahoo股市資料顯示截至2025年12月5日股本約新台幣15.741億元、已發行普通股約1.574億股；櫃買中心頁面顯示實收資本額約新台幣15.754億元，兩者時間點不同。2024永續報告書揭露2024年底員工68人；2023年年報揭露2023年員工65人、研發人員45人、研發人力占69%。主要股東名單截至2025年3月31日包括Foresee Pharmaceuticals, Inc.持股15.31%、昌達生化科技股份有限公司7.35%、鄭俊忠5.86%、許佩慈3.95%、許秀梅3.80%、黃瑞興1.40%、Larry Chuanming Duan 1.35%、大通託管先進星光先進總合國際股票指數1.12%、李宜軒0.97%、李德軒0.97%。公司定位為台美兩地生技醫藥公司，核心研發聚焦獨家穩定長效注射劑型SIF-LAI平台及罕見／嚴重疾病創新成分小分子藥物。

Business

主要商業模式為自有研發平台開發候選藥物，完成臨床、法規或階段性驗證後，透過區域授權、供貨、銷售分潤、里程金與權利金取得收入；公司本身並非典型大量製造銷售藥廠。核心產品為CAMCEVI／FP-001，即leuprolide mesylate長效注射劑。CAMCEVI 42mg六個月劑型用於晚期前列腺癌，已獲美國、加拿大、歐盟、台灣、以色列、英國等核准，並已於2022年4月在美國上市、2025年1月在德國上市，中國NMPA申請由中國授權夥伴長春金賽藥業受理審查。CAMCEVI ETM 21mg三個月劑型已於2025年8月25日獲美國FDA核准，預計由Intas旗下Accord BioPharma於美國商業化，歐洲審查仍在進行。FP-001 42mg亦拓展兒童中樞性性早熟CPP，Casppian三期臨床於2025年12月公布達主要療效指標，2026年5月完成最後一位病患最後一次訪視，94%病患達LH抑制目標，計畫2026年下半年向FDA送NDA；同一六個月劑型另由中國授權夥伴進行停經前乳癌三期臨床。新成分小分子方面，MMP-12抑制劑FP-025、FP-020及第三代MMP-12抑制劑已於2026年1月授權Primevera Therapeutics，逸達取得1,000萬美元簽約金、未來最高5.745億美元里程金與銷售權利金、以及Primevera 19%股權。ALDH2活化劑mirivadelgat／FP-045已於2025年第二季啟動PH-ILD二期WINDWARD試驗，2026年6月被選入挪威SLEIPNIR帕金森氏症二期a平台試驗。營收結構目前仍高度受里程金、供貨節奏與銷售分潤認列時點影響；公司公告2025全年合併營收約新台幣4.31億元、年增3%，2026年1月合併營收1,279萬元全數為CAMCEVI六個月劑型銷售分潤。

Outlook 2025–2028

2025至2028年成長動能主要來自四條線：第一，CAMCEVI六個月劑型在美國持續銷售分潤，歐洲自德國上市後逐步擴展，若中國、歐洲更多國家與其他區域上市進度順利，供貨、權利金與里程金有機會增加。第二，CAMCEVI ETM三個月劑型已獲美國FDA核准，預計2026年底美國上市，若J-Code、給付與通路導入順利，三個月與六個月雙劑型可提供醫師更彈性的前列腺癌治療選項。第三，CPP適應症已完成Casppian三期關鍵試驗並確認94% LH抑制結果，公司規劃2026年Q3至Q4向FDA送NDA、2026下半年至2027上半年向其他市場送件；若2027至2028年陸續核准，可能成為逸達下一個大適應症。第四，MMP-12授權案改善資金與降低後續研發支出，FP-045／mirivadelgat則同時推進PH-ILD與帕金森氏症早期臨床，若出現概念驗證數據，具授權或合作價值。主要風險包括：生技公司研發與法規時程高度不確定，CPP NDA審查、CMC、長期安全性或標籤結果可能延宕；CAMCEVI銷售受授權夥伴Intas、Accord Healthcare、長春金賽等商業化能力、各國藥價給付與醫師轉換意願影響；營收仍可能因里程金一次性認列與供貨批次而劇烈波動；原料藥、製劑代工、品質查廠及海外供應鏈任何中斷均可能影響供貨；前列腺癌與CPP市場已有Lupron Depot、Eligard、Trelstar、Zoladex、Firmagon、Orgovyx、Fensolvi、Triptodur等競品；FP-045、FP-020、FP-025等創新小分子仍屬早期或授權後開發階段，臨床失敗風險高。

Supply Chain

Upstream
  • 台灣神隆股份有限公司 1789 台股上市原料藥／製造供應鏈公司；媒體報導CAMCEVI新藥製造供應或原料藥代工研製由神隆負責，屬逸達CAMCEVI供應鏈重要台灣掛牌上游。
  • Fareva 法國CDMO／代工廠；2025年新聞提及CAMCEVI由逸達委託法國Fareva生產製造，美國經銷商直接自法國代工廠拉貨，非台股掛牌公司。
  • 臨床試驗醫院、CRO與法規顧問 支援CPP、PH-ILD、帕金森氏症等國際臨床試驗、數據管理、法規送件與安全性監測；多為未上市或海外機構，未逐一確認掛牌狀態。
Downstream
  • Intas Pharmaceuticals Ltd. 印度非台股掛牌藥廠；CAMCEVI美國市場授權夥伴，透過美國子公司Accord BioPharma負責CAMCEVI在美國商業化。
  • Accord BioPharma, Inc. Intas旗下美國特殊製劑子公司，負責CAMCEVI美國市場推廣與銷售，非台股掛牌公司。
  • Accord Healthcare 海外非台股掛牌藥品商業化夥伴；CAMCEVI於美國以外多區域含歐洲、加拿大、澳洲等由其或關係企業推動商業化。
  • 長春金賽藥業 GeneScience Pharmaceuticals 中國授權夥伴，負責CAMCEVI中國市場相關開發、申請與商業化；非台股掛牌公司。
  • Primevera Therapeutics, LLC 美國未上市／非台股掛牌公司；2026年取得逸達MMP-12抑制劑系列化合物全球獨家授權，後續承擔FP-020、FP-025與第三代MMP-12抑制劑研發及商業化。
  • EVERSANA 美國商業化服務公司；曾與Accord BioPharma合作支援CAMCEVI美國上市，非台股掛牌公司。

Competitors

  • AbbVie Inc. 美國上市藥廠；Lupron Depot與Lupron Depot-PED為leuprolide長效注射競品，直接競爭前列腺癌與CPP等GnRH agonist市場。
  • Tolmar Pharmaceuticals 美國非台股掛牌藥廠；Eligard用於前列腺癌、Fensolvi用於CPP，與CAMCEVI／FP-001在同類GnRH agonist長效注射市場競爭。
  • Ipsen／Recordati等triptorelin相關產品業者 非台股掛牌；Trelstar、Decapeptyl等triptorelin長效製劑在前列腺癌、性早熟或婦科適應症與leuprolide類產品競爭。
  • AstraZeneca 英國上市藥廠；Zoladex為goserelin長效植入劑，用於前列腺癌、乳癌與婦科適應症，屬GnRH類治療競品。
  • Myovant Sciences／Sumitomo Pharma／Pfizer相關商業化體系 Orgovyx為口服GnRH receptor antagonist，用於晚期前列腺癌，與注射型GnRH產品競爭；相關公司非台股掛牌。
  • Azurity Pharmaceuticals Triptodur為CPP用triptorelin六個月劑型，與逸達FP-001 CPP適應症定位相近；非台股掛牌。
  • 台灣微脂體股份有限公司 4152 台股上櫃公司；同屬特殊劑型／藥物傳輸平台型生技公司，但並非CAMCEVI同成分或同適應症的直接競品，列為台灣生技平台同業參考。
Sources（18）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.